Pancreatic Cancer Drug Daraxonrasib Nearly Doubles Survival in Major Trial, Now FDA-Approved
The pancreatic cancer drug daraxonrasib (brand name Rasonque) has become a significant new option for many Americans with advanced disease after the U.S. Food and Drug Administration approved it on August 26, 2026. This oral RAS inhibitor targets the mutations driving more than 90% of pancreatic ductal adenocarcinoma cases and produced clear survival gains versus … Read more